Parenteral Drug (India) Ltd. reported un-audited consolidated and standalone earnings results for the third quarter and nine months ended December 31, 2012. For the quarter, on consolidated basis, the company reported total income from operations (net) of INR 689.709 million compared to INR 937.476 million, loss from operations before other income, finance costs and exceptional items of INR 94.258 million compared to profit from operations before other income, finance costs and exceptional items of INR 124.189 million, loss from ordinary activities before tax of INR 252.785 million compared to profit from ordinary activities before tax of INR 6.388 million and net loss of INR 261.101 million or INR 10.09 per basic and diluted share compared to INR 2.854 million or INR 0.11 per basic diluted share for the last year.

For the nine months, on consolidated basis, the company reported total income from operations (net) of INR 2,131.099 million compared to INR 2,525.115 million, loss from operations before other income, finance costs and exceptional items of INR 301.061 million compared to profit from operations before other income, finance costs and exceptional items of INR 245.154 million, loss from ordinary activities before tax of INR 739.629 million compared to INR 81.838 million and net loss of INR 762.141 million or INR 29.469 per basic and diluted share compared to INR 111.175 million or INR 4.30 per basic and diluted share for the last year.

For the quarter, on standalone basis, the company reported loss from operations before other income, finance costs and exceptional items of INR 81.8 million compared to profit from operations before other income, finance costs and exceptional items of INR 97.71 million reported a year ago. Net loss was INR 205.23 million or INR 7.93 per basic and diluted share before and after extraordinary items compared to net loss of INR 5.912 million or INR 0.23 per basic and diluted share before and after extraordinary items reported a year ago. Net sales were INR 390.12 million compared to INR 842.46 million reported a year ago. Loss from ordinary activities before tax was INR 200.23 million compared to INR 0.74 million a year ago.

For the nine months, on standalone basis, the company reported loss from operations before other income, interest and exceptional items of INR 308.27 million compared to profit from operations before other income, finance costs and exceptional items of INR 159.19 million reported a year ago. Net loss was INR 672.81 million or INR 26.01 per basic and diluted share before and after extraordinary items compared to net loss of INR 128.15 million or INR 4.95 per basic and diluted share before and after extraordinary items reported a year ago. Net sales were INR 1,353.46 million compared to INR 1,704.23 million reported a year ago. Loss from ordinary activities before tax was INR 657.81 million compared to INR 112.62 million a year ago.